← Leaderboards
Neil McDonald
University Of Arizona
$487,878
Attributed
$1,463,635
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $309.5K · FY2015–19$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,463,635 · 1
By mechanism
R01$1,463,635 · 1
Top collaborators
- Hong-Yu Li5 shared
- Massimo Santoro5 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Roberta Diaz Brinton$56,323,258
- Frederick R Ahmann$6,617,685
- Massimo Santoro$487,878
- Elizabeth T Jacobs$4,207,163
- Jian-Kang Zhu$8,446,904
Others in their field
Top investigators on “Dose-Limiting”
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Louis J. Picker · Oregon Health And Science University$30,040,175
- David S Alberts · University Of Arizona$19,862,351
- Dan H. Barouch · Fred Hutchinson Cancer Center$17,645,273
- Gary R Morrow · University Of Rochester$14,808,256
- Erik Ian Tucker · Aronora, Inc.$13,137,321
Research focus
Dose-LimitingComputer SimulationDesignDoseAnimalsBaseComplexData AnalysesAssay DevelopmentCombatAutomobile DrivingBiological AvailabilityBiological MarkersBlood VesselsBenzimidazoleCancer Cell LineActive SitesCause Of DeathCell GrowthCell ProliferationCellsChromosomal RearrangementBiochemicalEffective Therapy
Grant awards (5)
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$276,428
R01 · FY2019 · CA
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$284,978
R01 · FY2018 · CA
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$284,978
R01 · FY2017 · CA
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$309,478
R01 · FY2016 · CA
Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer$307,773
R01 · FY2015 · CA